Research programme: echovirus therapeutics - Viralytics

Drug Profile

Research programme: echovirus therapeutics - Viralytics

Alternative Names: ECHO-1; EVATAK

Latest Information Update: 16 Aug 2013

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator ViroTarg
  • Developer Viralytics
  • Class Antineoplastics; Oncolytic viruses
  • Mechanism of Action Cell death stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Preclinical Gastric cancer; Ovarian cancer; Prostate cancer

Most Recent Events

  • 16 Aug 2013 Preclinical trials in Gastric cancer in Australia (Intraperitoneal)
  • 16 Aug 2013 Preclinical trials in Ovarian cancer in Australia (Intraperitoneal)
  • 16 Aug 2013 Preclinical trials in Prostate cancer in Australia (Intratumoural)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top